| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 17th February 2021 | Peter A. Thompson | 1,285,714 | Open or private purchase | $3.50 | $4,499,999.00 |
| 12th February 2021 | Carl L Gordon | 104,050 | Grant/award etc. | $13.00 | $1,352,650.00 |
| 12th February 2021 | Advisors Llc Orbimed | 104,050 | Grant/award etc. | $13.00 | $1,352,650.00 |
| 12th February 2021 | Advisors Llc Orbimed | 420,299 | Grant/award etc. | $13.00 | $5,463,887.00 |
| 12th February 2021 | Carl L Gordon | 420,299 | Grant/award etc. | $13.00 | $5,463,887.00 |
| 9th February 2021 | Advisors Llc Orbimed | 190,000 | Open or private purchase | $17.00 | $3,230,000.00 |
| 9th February 2021 | Advisors Llc Orbimed | 285,000 | Open or private purchase | $17.00 | $4,845,000.00 |
| 9th February 2021 | Carl L Gordon | 1,989,723 | Conversion of derivative | $0.00 | |
| 9th February 2021 | Carl L Gordon | 1,326,481 | Conversion of derivative | $0.00 | |
| 9th February 2021 | Carl L Gordon | 285,000 | Open or private purchase | $17.00 | $4,845,000.00 |
Prevail Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.
Ticker: PRVL
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1714798
Employees: 55
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Gain Therapeutics Aims For $40 Million IPO
25th February 2021
Biotech Bonanza: 2021 Outlook In A Post-Pandemic Year
11th January 2021